More good Celebrex news here
--------------------------------------------------------------------------------
Related Quotes
MTC
PFE
48 1/2
131 3/16
+1 1/16
+4 7/16
delayed 20 mins - disclaimer
Thursday February 11, 2:22 pm Eastern Time
Company Press Release
SOURCE: Monsanto Company
Celebrex(TM) Approved in Mexico - New Arthritis Treatment Now Cleared for Market in Three Largest Countries in the Americas
CHICAGO, Feb. 11 /PRNewswire/ -- G.D. Searle & Co., the pharmaceutical business unit of Monsanto Company (NYSE: MTC - news), and Pfizer Inc (NYSE: PFE - news) announced today that the Mexican Health Secretariat has approved Celebrex(TM) (celecoxib) for the treatment of the signs and symptoms of osteoarthritis and rheumatoid arthritis and for the management of pain. The product has already been cleared by regulatory agencies in the United States and Brazil for the arthritis indications.
''We are pleased that people with arthritis in Mexico will now have the benefit of this innovative and effective new product,'' said Al Heller, Searle's chief operating officer. ''With approval in the U.S., Brazil, and now Mexico, Celebrex will now be available to arthritis patients in the three largest countries in the Americas.'' It is estimated that more than eight million of Mexico's 100 million people suffer from arthritis.
Searle and Pfizer will promote Celebrex in all world markets except Japan. Additional Celebrex approvals are pending in more than 30 countries.
Searle, a global leader in arthritis products and educational programs, is the pharmaceutical sector of Monsanto Company. Searle develops, produces and markets prescription pharmaceuticals, including major products to treat arthritis, cardiovascular disease, cancer and its complications and insomnia, and to promote women's health. For more information on Searle, access www.searlehealthnet.com. As a life sciences company, Monsanto is committed to finding solutions to the growing global needs for food and health by sharing common forms of science and technology among agriculture, nutrition and health. In 1998, Monsanto reported sales of $8.6 billion and invested approximately $1 billion in research and development.
Pfizer Inc is a research-based, global healthcare company. Pfizer discovers and develops innovative, value-added products that improve the quality of life of people around the world and help them enjoy longer, healthier and more productive lives. The company has three business segments: health care, animal health and consumer health care, with products available in more than 150 countries. In 1998, the company reported revenues of over $13.5 billion and invested more than $2.2 billion in research and development. For more information on Pfizer, access www.pfizer.com.
For complete prescribing information, please call 1-877-CELECOXIB or consult www.celebrex.com on the Internet.
|
